Cargando…

Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients

PURPOSE: This study aimed to investigate AKT gene mutation status in Chinese breast cancer patients. METHODS: The study included 411 breast cancer patients hospitalized in Guangdong Provincial People’s Hospital (GDPH) from June 1, 2017 to September 27, 2018. Mastectomy or breast conserving surgery w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Lingzhu, Zhang, Guochun, Ren, Chongyang, Li, Xuerui, Mok, Hsiaopei, Jia, Minghan, Wang, Yulei, Chen, Bo, Li, Kai, Cao, Li, Li, Cheukfai, Xiao, Weikai, Lai, Jianguo, Lin, Jiali, Wei, Guangnan, Li, Yingzi, Zhang, Yuchen, Chen, Xiaoqing, Liao, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039050/
https://www.ncbi.nlm.nih.gov/pubmed/33854375
http://dx.doi.org/10.2147/CMAR.S299624
_version_ 1783677510183026688
author Wen, Lingzhu
Zhang, Guochun
Ren, Chongyang
Li, Xuerui
Mok, Hsiaopei
Jia, Minghan
Wang, Yulei
Chen, Bo
Li, Kai
Cao, Li
Li, Cheukfai
Xiao, Weikai
Lai, Jianguo
Lin, Jiali
Wei, Guangnan
Li, Yingzi
Zhang, Yuchen
Chen, Xiaoqing
Liao, Ning
author_facet Wen, Lingzhu
Zhang, Guochun
Ren, Chongyang
Li, Xuerui
Mok, Hsiaopei
Jia, Minghan
Wang, Yulei
Chen, Bo
Li, Kai
Cao, Li
Li, Cheukfai
Xiao, Weikai
Lai, Jianguo
Lin, Jiali
Wei, Guangnan
Li, Yingzi
Zhang, Yuchen
Chen, Xiaoqing
Liao, Ning
author_sort Wen, Lingzhu
collection PubMed
description PURPOSE: This study aimed to investigate AKT gene mutation status in Chinese breast cancer patients. METHODS: The study included 411 breast cancer patients hospitalized in Guangdong Provincial People’s Hospital (GDPH) from June 1, 2017 to September 27, 2018. Mastectomy or breast conserving surgery was performed, and tissue samples were subjected to next-generation sequencing (NGS) to determine AKT gene mutation status. Meanwhile, the expression of human epidermal growth factor receptor 2 (Her2), progesterone receptor (PR), and estrogen receptor (ER) was analyzed by immunohistochemistry staining. The Cancer Genome Atlas (TCGA) database was used for comparative studies. RESULTS: Patients in the GDPH cohort had an older age (P < 0.001), higher postmenopausal rate (P < 0.001), larger tumor size (P < 0.001), higher histologic type of infiltrating duct cancer (P < 0.001), higher metastatic rate (P < 0.001), higher expression of ER (P = 0.015) and HER2 (P < 0.001), and higher percentage of the HR/HER2 subtype (P < 0.001) than those in the TCGA cohort. The GDPH cohort displayed lower rates of overall AKT and AKT3 mutation (P < 0.001), but a higher AKT1 mutation rate (P < 0.0001) compared with the TCGA cohort. Notably, the NGS studies identified missense mutation and copy number amplification as the most common AKT variation type in the GDPH and TCGA cohorts, respectively. Specifically, E17K mutation in AKT1 was predominantly detected in GDPH cohort, while being absent in TCGA cohort. Moreover, in the GDPH cohort, AKT variation was correlated with a number of clinicopathological variables, including age over 50, HER2-, HR+/HER2-, and PR+. CONCLUSION: Patients in the GDPH cohort had lower rates of AKT and AKT3 mutation and higher AKT1 mutation rate than those in the TCGA cohort, while harboring missense mutations detected predominantly as E17K mutation in AKT1. In GDPH cohort, there were correlations between AKT mutation and the clinicopathological characteristics of patients.
format Online
Article
Text
id pubmed-8039050
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-80390502021-04-13 Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients Wen, Lingzhu Zhang, Guochun Ren, Chongyang Li, Xuerui Mok, Hsiaopei Jia, Minghan Wang, Yulei Chen, Bo Li, Kai Cao, Li Li, Cheukfai Xiao, Weikai Lai, Jianguo Lin, Jiali Wei, Guangnan Li, Yingzi Zhang, Yuchen Chen, Xiaoqing Liao, Ning Cancer Manag Res Original Research PURPOSE: This study aimed to investigate AKT gene mutation status in Chinese breast cancer patients. METHODS: The study included 411 breast cancer patients hospitalized in Guangdong Provincial People’s Hospital (GDPH) from June 1, 2017 to September 27, 2018. Mastectomy or breast conserving surgery was performed, and tissue samples were subjected to next-generation sequencing (NGS) to determine AKT gene mutation status. Meanwhile, the expression of human epidermal growth factor receptor 2 (Her2), progesterone receptor (PR), and estrogen receptor (ER) was analyzed by immunohistochemistry staining. The Cancer Genome Atlas (TCGA) database was used for comparative studies. RESULTS: Patients in the GDPH cohort had an older age (P < 0.001), higher postmenopausal rate (P < 0.001), larger tumor size (P < 0.001), higher histologic type of infiltrating duct cancer (P < 0.001), higher metastatic rate (P < 0.001), higher expression of ER (P = 0.015) and HER2 (P < 0.001), and higher percentage of the HR/HER2 subtype (P < 0.001) than those in the TCGA cohort. The GDPH cohort displayed lower rates of overall AKT and AKT3 mutation (P < 0.001), but a higher AKT1 mutation rate (P < 0.0001) compared with the TCGA cohort. Notably, the NGS studies identified missense mutation and copy number amplification as the most common AKT variation type in the GDPH and TCGA cohorts, respectively. Specifically, E17K mutation in AKT1 was predominantly detected in GDPH cohort, while being absent in TCGA cohort. Moreover, in the GDPH cohort, AKT variation was correlated with a number of clinicopathological variables, including age over 50, HER2-, HR+/HER2-, and PR+. CONCLUSION: Patients in the GDPH cohort had lower rates of AKT and AKT3 mutation and higher AKT1 mutation rate than those in the TCGA cohort, while harboring missense mutations detected predominantly as E17K mutation in AKT1. In GDPH cohort, there were correlations between AKT mutation and the clinicopathological characteristics of patients. Dove 2021-04-07 /pmc/articles/PMC8039050/ /pubmed/33854375 http://dx.doi.org/10.2147/CMAR.S299624 Text en © 2021 Wen et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wen, Lingzhu
Zhang, Guochun
Ren, Chongyang
Li, Xuerui
Mok, Hsiaopei
Jia, Minghan
Wang, Yulei
Chen, Bo
Li, Kai
Cao, Li
Li, Cheukfai
Xiao, Weikai
Lai, Jianguo
Lin, Jiali
Wei, Guangnan
Li, Yingzi
Zhang, Yuchen
Chen, Xiaoqing
Liao, Ning
Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
title Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
title_full Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
title_fullStr Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
title_full_unstemmed Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
title_short Characterization of AKT Somatic Mutations in Chinese Breast Cancer Patients
title_sort characterization of akt somatic mutations in chinese breast cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039050/
https://www.ncbi.nlm.nih.gov/pubmed/33854375
http://dx.doi.org/10.2147/CMAR.S299624
work_keys_str_mv AT wenlingzhu characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT zhangguochun characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT renchongyang characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT lixuerui characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT mokhsiaopei characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT jiaminghan characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT wangyulei characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT chenbo characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT likai characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT caoli characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT licheukfai characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT xiaoweikai characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT laijianguo characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT linjiali characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT weiguangnan characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT liyingzi characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT zhangyuchen characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT chenxiaoqing characterizationofaktsomaticmutationsinchinesebreastcancerpatients
AT liaoning characterizationofaktsomaticmutationsinchinesebreastcancerpatients